Hantz Financial Services Inc. Purchases 35,294 Shares of Enovis Co. (NYSE:ENOV)

Hantz Financial Services Inc. boosted its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 18.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 224,396 shares of the company's stock after buying an additional 35,294 shares during the period. Hantz Financial Services Inc. owned 0.40% of Enovis worth $9,660,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Ridgewood Investments LLC purchased a new position in Enovis during the second quarter valued at $44,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Enovis during the third quarter valued at about $55,000. Innealta Capital LLC bought a new stake in shares of Enovis in the second quarter worth about $65,000. Benjamin F. Edwards & Company Inc. lifted its position in shares of Enovis by 28.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock worth $76,000 after buying an additional 371 shares in the last quarter. Finally, FMR LLC boosted its stake in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after buying an additional 484 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Trading Up 0.7 %

Shares of ENOV stock traded up $0.36 during trading hours on Friday, reaching $48.81. 249,656 shares of the stock were exchanged, compared to its average volume of 581,045. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -22.29 and a beta of 1.91. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The company's 50-day moving average price is $43.18 and its 200-day moving average price is $44.91. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter in the previous year, the business earned $0.56 earnings per share. The company's revenue for the quarter was up 21.0% compared to the same quarter last year. As a group, equities analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ENOV. Needham & Company LLC reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Evercore ISI decreased their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 1st. JPMorgan Chase & Co. lowered their price objective on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. Finally, JMP Securities started coverage on shares of Enovis in a report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Enovis presently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.